Hyperfine (HYPR) vs TransMedics Group (TMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TransMedics Group (TMDX) has outperformed Hyperfine (HYPR) over the past year, losing 33.1% versus a loss of 55.0%. Over five years, TMDX leads with a +197.6% price change compared with -90.5% for HYPR. TransMedics Group is the larger company by market cap ($2.74 billion vs $99.7 million), about 27.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HYPR | TMDX |
|---|---|---|
| Share price | $0.9401 | $79.00 |
| Market cap | $99.70M | $2.74B |
| 1-day change | +10.73% | -2.55% |
| YTD return | -3.97% | -35.06% |
| 1-year return | -55.02% | -33.08% |
| 5-year return | -90.54% | +197.55% |
| P/E ratio (TTM) | — | 20.47 |
| Forward P/E | — | 35.05 |
| EPS (TTM) | $-0.37 | $3.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $605.49M |
| Revenue growth (YoY) | — | +37.13% |
| Net income (latest FY) | — | $190.29M |
| Gross margin | — | 59.92% |
| Operating margin | — | 17.93% |
| Net margin | — | 31.43% |
| 52-week high | $2.22 | $156.00 |
| 52-week low | $0.754 | $60.11 |
| Distance from 52-week high | -57.65% | -49.36% |
| Analyst consensus | none | buy |
| Avg. price target upside | +115.93% | +26.35% |
| Average volume | 611.89K | 820.41K |
| Shares outstanding | 90.99M | 34.68M |
| Employees | 102 | 898 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TransMedics Group is about 27.5 times larger than Hyperfine by market value ($2.74B vs $99.70M).
- TMDX has outperformed HYPR by 21.9 percentage points over the past year.
About Hyperfine
HYPR stock →Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 102 employees
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 898 employees
HYPR vs TMDX FAQ
Which is bigger, Hyperfine or TransMedics Group?
TransMedics Group (TMDX) is larger, with a market capitalization of $2.74B compared with $99.70M for Hyperfine (HYPR).
Which stock has performed better over the past year, HYPR or TMDX?
TMDX returned -33.08% over the past 12 months, compared with -55.02% for HYPR (price return, excluding dividends). Past performance does not predict future results.
Are Hyperfine and TransMedics Group in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.